RSC, February Interplay between enzymes and. clearance and intracellular concentration of drugs. Centre for Applied Pharmacokinetic Research
|
|
- Alicia Fox
- 5 years ago
- Views:
Transcription
1 RSC, February 2014 Interplay between enzymes and transporters in defining hepatic drug clearance and intracellular concentration of drugs J Brian Houston Centre for Applied Pharmacokinetic Research (CAPkR)
2 Three elements of mechanism-based prediction of human PK In vitro kinetics in multiple systems ADME & DDI Predictions (static and dynamic) Modelling & Simulation (PBPK)
3 Generic view of drug kinetics in hepatocytes: Various processes defining drug intracellular concentration Intracellular binding & trafficking Transporters Efffux Challenges To describe all processes To understand interplay & hence holistically model Media Passive diffusion D D D Intracellular unbound conc M Clearance by microsomal/cytosolic enzymes
4 Extending Classic Hepatic Clearance Models: Use of CL int,app to delineate transporters & enzymes and their Interplay Prediction (static) equations well established: e.g. well-stirred liver model Qh fub CLint CL Q h fu b CL int Extended with use of Cl int,app to encompass hepatocellular sequential processes (Interplay model) based on Sugiyama and Pang. CL int, app CL int, met CL int, active CL int, pass CL CL CL int, met int, pass int, eff
5 CL int,app Interplay of transporters and enzymes High passive permeability reduces to CL int,met Low passive permeability (with minimal effux) reduces to CL int,active Various intermediate cases. The second term collective Kp u (partition coefficient for unbound drug)
6 In vitro tools for assessment of hepatic uptake Hepatocytes: Suspension culture - direct cell uptake (oil separation) Plated cells (also sandwich configuration) Single time points or full time course of uptake & metabolism Comparative scaled activity in hepatocytes relative to microsomes (subcellular l preparation) Sometimes rat better option than human Higher activity and less confounding issues surrounding preparation and storage Minimal inter-individual variation Potential extrapolation to human CL terms main metric, and for inhibition DDIs K i where CL i = CL control / 1+K i
7 Characterisation of extent of hepatic uptake What are we measuring with Kp u? Kp u = Cell to medium (plasma) unbound concentration ratio Kp u CL int, uptake CL CL int, passive int, passive [True Kpu - at steady state when no metabolism or efflux] Kp u CL int, pass CL int, uptake CL CL [Apparent Kp u ] CL int, pass int, efflux int, met Contrasts with Kp total (ratio of total concentrations) which reflects both uptake and intracellular binding Kp u = fu cell Kp total Used together estimates intracellular drug concentration
8 Comparison of microsomes and hepatocytes Evidence for hepatic uptake affecting CL and DDI prediction If active uptake process occurring, substrate or inhibitor may show higher affinity in hepatocytes compared to microsomes i.e. lower K m or K i as [S] u,plasma << [S] u,liver or [I] u,plasma << [I] u,liver K pu, K imicrosome, K i, hepatocyte Km, CL int, microsome microsome mcr m K CL hepatocyte m, hepatocyte int, hepatocyte microsome
9 Impact of hepatic intracellular binding?: K i Microsomes vs. Hepatocytes (µm) Ki Hepa atocytes (n= 7 inhibitors, n=21 pathways) 100 Inhibitor Cell-to-Media Ratio Ki Microsomes (µm) MCZ FXT KCZ FVX QUI OMP FCZ (Kp total ) Good agreement between K i Fluconazole values in both systems (both Quinine corrected for non specific binding) Fl Fluvoxamine Kp u approximately 1 Miconazole Ketoconazole Fluoxetine Omeprazole Saquinavir Nelfinavir Ritonavir Brown et al, DMD 2007
10 Lack of impact of hepatic uptake: Microsomal & Hepatocyte K i ratio vs. Kp total / Hepato ocyte Ki Micro osome Ki Kp C/M totalt Ratio Kp total differ over 3 orders of magnitude No correlation between K i ratio and Kp total (n = 27) Brown et al, DMD 2007
11 Kp u = 1 importance of uptake transporters for 16 drugs in rat (Yabe et al DMD 2011) Kp u CL CL int, uptake int, passive CL int, passive Pdiff)1000 Kpu (CLuptake/P( 1 Pravastat atin Rosuvastat atin Atorvastat atin Cerivastat atin Pitavastat atin Saquinav avir Ritonav avir Telmisarta tan Olmesarta tan Valsarta tan Clarithromyc ycin Erythromyc ycin Repaglinid ide Nateglinid ide Fexofenadin dine Bosenta tan Kp u (CL uptake /P diff ) 250-fold range (erythromycin and atorvastatin).
12 Covariate analysis log Pdif ff ll log fucel Log D Log D7.4 Useful for cross-species and cross-systems extrapolation But no statistical relationship between: Log D and any active uptake parameters
13 (µm) Ki Hepa atocytes Interplay examples - Kp u = 1 : actively transported drugs (n= 7 inhibitors, n=21 pathways) 100 Inhibitor Cell-to-Media Ratio Saquinavir Ki Microsomes (µm) Enoxacin MCZ FXT KCZ FVX QUI OMP FCZ (Kp) Good agreement between K i Fluconazole values in both systems (except Quinine the higher affinity inhibitors) Fl Fluvoxamine Kpu approximately 1 Miconazole Ketoconazole Fluoxetine Omeprazole Saquinavir Nelfinavir Ritonavir Brown et al, DMD 2007
14 Example 1:Enoxacin inhibition of theophylline oxidation Sbt Substantial tilddi reported tdin humans and rats Microsomes Hepatocytes 100 THEO 0.5KM 100 activity % of control No significant inhibition Ki >1000 µm THEO K M THEO 2KM activity % of control Competitive inhibition Ki = µM (n=3) [Enoxacin] (µm) [Enoxacin] (µm) Significantly more potent (>20) inhibition in cells vs. microsomes Active uptake of enoxacin Similar scenario observed with erythromycin Brown et al, 2010
15 Example 2: Inhibition of CYP3A by HIV protease inhibitors nelfinavir and saquinavir Well documented examples of actively transported drugs with substantial DDIs Hepatocyte-microsomal difference in Ki to be expected Similar scenario to enoxacin and erythromycin?
16 Saquinavir metabolism and uptake in rat 50 n/g liver r) nmol/mi v ( )4040 Permeability 50ml/min/g liver 30 Clint >350 ml/min/g liver 20 Clint 50 ml/min/g liver 10 Metabolism microsomes Hepatocytes t Uptake hepatocytes [SQV] M Uptake is rate limiting and defines CL
17 Hepatic uptake and microsomal:hepatocyte Km & Ki ratios for saquinavir and nelfinavir Drug (Kp total ) Microsomal:hepatocellular ratio K m K i K pu Saquinavir (306) Nelfinavir (3350) Opposite effect to enoxacin & erythromycin cases Parker et al, DMD 2008
18 Framework for interplay of metabolism & transporters t on Kp u (Intermediate permeability 0.1 ml/min/m cells) Enoxacin, erythromycin Saquinavir,, nelfinavir No efflux or tissue binding
19 Example 3: Repaglinide-Gemfibrozil DDI Inhibition of both hepatic uptake and metabolism Plasma Liver Repaglinide Passive UGT X CYP2C8 X Metabolites OATP1B1 CYP3A4 X - inhibition by GFZ and GFZ-glucuronide DDI at both transporter and P450 level - sequential effect
20 Repaglinide uptake in human hepatocytes 100 Uptak ke Rate (pmoles s/mg protein/mi in) Repaglinide Concentration (µm) Contribution to total uptake (%) Repaglinide concentration (µm) - - Total uptake - - Passive component (4 C) --- Active component (simulated data) Km = 14.1 µm CL uptake 5-fold greater than the passive component at therapeutic concentrations IC5043and74µM for GFZ and GFZ-glucuronide, respectively
21 Comparison of contribution (based on Clints) of pathways across in vitro systems A % Contrib bution Hepatocytes Bution % Contribu S9 % Contrib Cbution HLM 0 M1 M2 M4 Gluc 0 M1 M2 M4 Gluc 0 M1 M2 M4 Gluc CYP3A4 CYP2C8 UGT M2 contributed similar % in S9 and hepatocytes (66% in vivo), ) needs aldehyde dehydrogenase to drive pathway. 5% contribution of M2 observed in HLM increased importance of M1 and M4 Similar contribution of CYP3A4 and CYP2C8 in S9 and hepatocytes Säll et al, DMD 2012
22 Inhibition of CYP2C8 by Gemfibrozil in vitro Using repaglinide depletion and rosiglitazone para- hydroxylation Competitive inhibition (red bars) - Microsomal/hepatocyte ratios 7 and 3 IC50 (µm) Time dependant inhibition, with pre-incubation (blue bars) - Microsomal/hepatocyte t ratio 24 and 44 [greater accumulation of glucuronide?] Microsomes Hepatocytes
23 Prediction of Repaglinide-Gemfibrozil DDI Obs Predicted from A interplay model fibrozil Repaglinide AUC in the presence of gemf and its glucuronide 0
24 Summary Use of rat hepatocytes provides a comprehensive package of clearance mechanisms for PBPK modelling to delineate intracellular events. Kp parameters particularly useful. Allows resolution of cellular binding and active transport processes. Unbound intracellular drug concentration needed consequences of transporters. Certain parameters are translatable to humans (P diff, fu cell )
25 Acknowledgements Aleksandra Galetin, David Hallifax Jane Alder, Hayley Brown, Carina Cantrill, Carolina Säll, Alison Wilby, Yoshiyuki Yabe Member companies of Centre for Applied Pharmacokinetic Research (CAPkR) Consortium
26 Repaglinide metabolism in human hepatocytes, S9 and microsomes M1 M2 CYP2C8/3A4 UGT1A1/1A3 M4 Repaglinide Repaglinide - glucuronide M5 Previous in vitro study identified M1 and M4 as major metabolites M0-OH M2 reported as major in vivo metabolite (66% of dose excreted in faeces and urine) No in vitro data available to confirm predominant role of CYP2C8 in repaglinide metabolism
Under prediction of hepatic clearance from in vitro studies: prospects for resolution. J Brian Houston
DDI, Seattle, June 2018 Under prediction of hepatic clearance from in vitro studies: prospects for resolution J Brian Houston Centre for Applied Pharmacokinetic Research (CAPkR) Scaling up in vitro parameters
More informationAssessing the role of hepatic uptake in drug clearance - Pharmacokinetic and experimental considerations
Assessing the role of hepatic uptake in drug clearance - Pharmacokinetic and experimental considerations Peter Webborn ISSX Short course Toronto 2013 1 Defining the why, when and how of Transporter studies
More informationImportance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data
pubs.acs.org/crt Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data Nina Isoherranen,* Justin D. Lutz, Sophie
More informationRISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationCulture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug nteraction Chuang Lu Millennium, The Takeda Oncology Company Cambridge, MA, USA DD 205, Seattle, 6/29/205
More informationIn vitro substrate-dependent inhibition of OATP1B1 and its impact on DDI prediction
SSX 3 rd Annual Conference (Oct 11, 2018) In vitro substrate-dependent inhibition of OATP1B1 and its impact on DDI prediction Yoshitane Nozaki, PhD DMPK Tsukuba Organic Anion Transporting Polypeptide (OATP)
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationKinetic characterization of rat hepatic uptake of 16 actively transported drugs. Yoshiyuki Yabe, Aleksandra Galetin and J Brian Houston
DMD Fast Forward. Published on July 5, 2011 as doi:10.1124/dmd.111.040477 Kinetic characterization of rat hepatic uptake of 16 actively transported drugs Yoshiyuki Yabe, Aleksandra Galetin and J Brian
More informationEvaluation of Drug-Drug Interactions FDA Perspective
Evaluation of Drug-Drug Interactions FDA Perspective Kellie Schoolar Reynolds, Pharm.D. Deputy Director Division of Clinical Pharmacology IV Office of Clinical Pharmacology Office of Translational Sciences
More informationPrediction of in vivo hepatic clearance and DDI of OATP substrates: Comparison of different in vitro approaches. Yuichi Sugiyama
Prediction of in vivo hepatic clearance and DDI of OATP substrates: Comparison of different in vitro approaches. Yuichi Sugiyama Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, Research Cluster for
More informationSimultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A. Comprehensive Mechanistic Model
JPET Fast This Forward. article has not Published been copyedited on and December formatted. The 21, final 2011 version as may DOI:10.1124/jpet.111.187112 differ from this version. Simultaneous Assessment
More informationSimultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model S
Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2/2/2/jpet..872.dc 52-3/2/34-2 5$25. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 34,
More informationThe Future of In Vitro Systems for the Assessment of Induction and Suppression of Enzymes and Transporters
The Future of In Vitro Systems for the Assessment of Induction and Suppression of Enzymes and Transporters AAPS, San Diego November 6 th, 2014 Andrew Parkinson, XPD Consulting Lisa Almond, Simcyp-Certara
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationFDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)
FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance) Kellie S. Reynolds, Pharm.D. Deputy Director, Division of Clinical Pharmacology IV Office of Clinical Pharmacology (OCP) Office of
More informationSupporting information
Supporting information Intracellular drug bioavailability: a new predictor of system dependent drug disposition Mateus, André 1* ; Treyer, Andrea 1* ; Wegler, Christine 1,2 ; Karlgren, Maria 1 ; Matsson,
More informationThe extended clearance model and its use for the interpretation of hepatobiliary elimination data
ADMET & DMPK 3(1) (2015) 1-14; doi: 10.5599/admet.3.1.144 Open Access : ISSN : 1848-7718 Review http://www.pub.iapchem.org/ojs/index.php/admet/index The extended clearance model and its use for the interpretation
More informationPREDICTING PHARMACOKINETICS FOLLOWING TOPICAL APPLICATION USING NON-ANIMAL METHODS IAN SORRELL, MI-YOUNG LEE, RICHARD CUBBERLEY
PREDICTING PHARMACOKINETICS FOLLOWING TOPICAL APPLICATION USING NON-ANIMAL METHODS IAN SORRELL, MI-YOUNG LEE, RICHARD CUBBERLEY UNILEVER APPLICATIONS KINETICS Need for estimates of local and systemic concentrations
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationStrategy on Drug Transporter Investigation Why, How, Which & When. Jasminder Sahi
Strategy on Drug Transporter Investigation Why, How, Which & When Jasminder Sahi Intestine Drug Absorption PEPT1 OATPs MCTs AE2 Epithelial Cell MCTs MRP3 Liver Excretion via Liver Kidney MRPs OATPs N PT1
More informationDrug Interactions, from bench to bedside
Drug Interactions, from bench to bedside Candidate to Market, The Paterson Institute for Cancer Research, Manchester, UK Michael Griffin PhD Overview of presentation To understand the importance of drug-drug
More informationSupplemental Information
Supplemental Information Article Title:The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Co-Administration with
More informationDRUG METABOLISM AND PHARMACOKINETICS (DMPK) Lena Gustavsson, H. Lundbeck A/S, November 2015
DRUG METABOLISM AND PHARMACOKINETICS (DMPK), H. Lundbeck A/S, LEGU@lundbeck.com November 2015 DMPK in Drug Discovery and Development Agenda Introduction Optimizing pharmacokinetic properties Absorption
More informationComparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?
Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Brian Ogilvie, Ph.D. VP Scientific Consulting XenoTech, LLC bogilvie@xenotechllc.com 14 Jun, 2018
More informationKinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs
9-9556//39-88 84$25. DRUG METOLISM ND DISPOSITION Vol. 39, No. Copyright 2 by The merican Society for Pharmacology and Experimental Therapeutics 4477/37552 DMD 39:88 84, 2 Printed in U.S.. Kinetic Characterization
More informationMuhammad Fawad Rasool Feras Khalil Stephanie Läer
Clin Pharmacokinet (2015) 54:943 962 DOI 10.1007/s40262-015-0253-7 ORIGINAL RESEARCH ARTICLE A Physiologically Based Pharmacokinetic Drug Disease Model to Predict Carvedilol Exposure in Adult and Paediatric
More informationBuilding innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches
Building innovative drug discovery alliances Hepatic uptake and drug disposition o in vitro and in silico approaches Dr Beth Williamson Evotec AG, 2017 Outline Importance of predicting clearance In vitro
More informationCore Data Set CYP2D6 Metabolism
Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationPrediction of DDIs Arising from CYP3A Induction Using a Physiologically-based Dynamic Model. Lisa Almond 22 nd June 2016
Prediction of DDIs Arising from CYP3A Induction Using a Physiologically-based Dynamic Model Lisa Almond 22 nd June 2016 Growing impact of PBPK on drug labels Revatio (Sildenafil) Pulmonary Arterial Hypertension
More informationCarolina Säll, J. Brian Houston, and Aleksandra Galetin
1521-9X/12/47-1279 1289$25. DRUG METABOLISM AND DISPOSITION Vol. 4, No. 7 Copyright 212 by The American Society for Pharmacology and Experimental Therapeutics 45286/3773739 DMD 4:1279 1289, 212 A Comprehensive
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationWelcome to the webinar... We will begin shortly
Welcome to the webinar... We will begin shortly Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir,
More informationPBPK modeling of renal impairment what is missing?
PBPK modeling of renal impairment what is missing? Aleksandra Galetin Centre for Applied Pharmacokinetic Research, University of Manchester, UK Outline of the presentation Physiological changes in renal
More informationMEDCHEM 570. First Midterm. January 30, 2015
Name MEDCHEM 570 First Midterm January 30, 2015 Instructions: Exam packet totals 7 pages. The last page has a 5 points extra credit question. If you need additional space for a question go to the back
More informationCurrent Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
More information104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
More informationApplication of PBPK Modeling and Simulations in Drug Development
Application of PBPK Modeling and Simulations in Drug Development Ping Zhao Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More informationDrug Interactions: Definition
Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health December 9, 2010 Drug Interactions:
More informationDrug disposition classification systems: A comparative review of BDDCS, ECCS and ECCCS
Novartis Drug disposition classification systems: A comparative review of BDDCS, ECCS and ECCCS Birk Poller, Gian Camenisch - Novartis SOLVO - Meet The Experts Transporter Conference April 26, 2018 Drug
More informationSupplemental Materials
Supplemental Materials Evaluation of Ketoconazole and its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin and
More informationA unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationWhat Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug
Title What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the U.S. FDA in 2015 Jingjing Yu, Zhu Zhou, Katie H. Owens, Tasha K. Ritchie,
More informationHigh-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage
High-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage David M. Stresser, Ph.D. Program Manager BD Gentest SM Contract Research Services November 11, 2009 Presentation
More informationHTPK: Conducting PK modeling and
HTPK: Conducting PK modeling and simulations at high speed November 5, 2018 Robert Fraczkiewicz, David Miller, Marvin Waldman, Robert D. Clark Slide 1 Session Description and Objectives HTPK lightens the
More informationMinireview. Low-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists
1521-009X/43/12/1917 1928$25.00 http://dx.doi.org/10.1124/dmd.115.066431 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 43:1917 1928, December 2015 Copyright ª 2015 by The American Society for Pharmacology
More informationDrug Interactions. Drug Interactions: Definition
Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health Drug Interactions: Definition The pharmacologic
More informationPharmacogenetics and Pharmacokinetics
Chapter 2 Pharmacogenetics and Pharmacokinetics Mauro Saivezzo/ShutterStock, Inc. L earning O bjectives Upon completion of this chapter, the student will be able to: 1. Recognize the influence of genetic
More informationXTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose
XTreme 200 Human Liver Microsomes Lot No. 1710084 Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H2610 0.5 ml at 20 mg/ml H2620 1.0 ml at 20 mg/ml H2630
More informationPhysiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions. Involving Inhibitory Metabolite A Case Study of Amiodarone
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite A Case Study of Amiodarone Yuan Chen, Jialin Mao, Cornelis E. C.A. Hop Drug Metabolism and
More informationComplexities of Hepatic Drug Transport: How Do We Sort It All Out?
Complexities of Hepatic Drug Transport: How Do We Sort It All Out? Keith A. Hoffmaster Pfizer Research Technology Center Cambridge, MA NEDMDG 2005 Summer Symposium 06.08.2005 The Challenge Intestinal uptake
More informationPrediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the Liver
0031-6997/98/5003-0387$03.00/0 PHARMACOLOGICAL REVIEWS Vol. 50, No. 3 Copyright 1998 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. Prediction of Pharmacokinetic
More informationBiopharmaceutics. Tips Worth Tweeting. Contributor: Sandra Earle
Biopharmaceutics C H A P T E R 2 Contributor: Sandra Earle The physiochemical properties of drugs determine how they will move and interact with the body. By understanding a few principles, predictions
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationMonica Edholm Medica Medic l a Pr oducts Agency
EMA EFPIA workshop Break-out session no. 2 Case Study Title: M&S for dose adjustment in impaired patients M&S for dose adjustment in renally Monica Edholm MedicalProducts Agency Disclaimer: The views expressed
More informationCryo Characterization Report (CCR)
Human Cryopreserved Hepatocytes Lot number: HUM4061B Date: October 19, 2014 Cryo Characterization Report (CCR) Lot Overview Qualification Catalog Number Quantity Cryopreserved human hepatocytes, Qualyst
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationYuichi Sugiyama Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, Research Cluster for Innovation,
Can the Prediction of Complex Transporter (uptake, efflux)/ Enzyme-mediated Drug-drug Interactions be Possible Using a Proposed Physiologically-based Pharmacokinetic (PBPK) Model with in Vitro Ki Values?
More informationDevelopment & Characterization of Pooled and Plated Hepatocytes to Support the Evolving DMPK Landscape
Development & Characterization of Pooled and Plated Hepatocytes to Support the Evolving DMPK Landscape April Downey Senior Production and Inventory Scientist In Vitro adowney@xenotechllc.com www.xenotechllc.com
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationCytochrome P450 Suppression in Human Hepatocyte Cultures by Small and Large Molecules. George Zhang, Ph.D. April 18, 2012
Cytochrome P450 Suppression in Human Hepatocyte Cultures by Small and Large Molecules George Zhang, Ph.D. April 18, 2012 Presentation Overview Regulatory guidance Brief review on drug-drug (Disease) interactions
More informationBrainteaser NK-1 receptor antagonists
Brainteaser K-1 receptor antagonists 96 Strategies: Lower overall lipophilicity of compound - find areas of the molecule where logd can be lowered Identify and block sites of metabolism major site of metabolism
More informationLeslie Z. Benet, PhD. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University of California San Francisco
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Drug Interactions Leslie Z. Benet, PhD Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University
More informationSILOFAST Capsules (Silodosin)
Published on: 10 Jul 2014 SILOFAST Capsules (Silodosin) Composition SILOFAST-4 Capsules Each hard gelatin capsule contains: Silodosin 4 mg Approved colours used in capsule shell SILOFAST-8 Capsules Each
More informationRate limiting steps in hepatic drug clearance: comparison of. hepatocellular uptake and metabolism with microsomal metabolism
DMD This Fast article Forward. has not been Published copyedited on and formatted. April 21, The 2008 final as version doi:10.1124/dmd.108.020917 may differ from this version. Rate limiting steps in hepatic
More informationSimultaneous Assessment In Vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a Media Loss Approach s
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/02/07/dmd.117.079590.dc1 1521-009X/46/4/405 414$35.00 https://doi.org/10.1124/dmd.117.079590 DRUG
More informationModeling and predicting drug pharmacokinetics in patients with renal impairment
For reprint orders, please contact reprints@expert-reviews.com Modeling and predicting drug pharmacokinetics in patients with renal impairment Expert Rev. Clin. Pharmacol. 4(2), 261 274 (2011) Karen Rowland
More informationEffects of Liver Disease on Pharmacokinetics
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver
More informationWhen does the rate-determining step in the hepatic clearance of a drug switch from
When does the rate-determining step in the hepatic clearance of a drug switch from sinusoidal uptake to all hepatobiliary clearances? Implications for predicting drug-drug interactions Gabriela I. Patilea-Vrana
More informationDetail features... 1
PBPK Modelling and its Applications to Predict Transporter-Mediated Drug-Drug Interactions Masoud Jamei Senior Scientific Advisor, Head of M&S M.Jamei@Simcyp.com NEDMDG 14 th June 211, New England, USA
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University
More informationEvaluation of Cryopreserved Human Hepatocytes as an Alternative In Vitro System to
DMD Fast This Forward. article has not Published been copyedited on and November formatted. The 28, final 2006 version as may doi:0.24/dmd.06.0569 differ from this version. Title Page Evaluation of Cryopreserved
More informationInfluence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments
Influence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments MARIA BIANCA ABRUDAN* 1, DANA MARIA MUNTEAN 1, DANIELA SAVETA POPA 2, LAURIAN VLASE 1, ANA-MARIA
More informationEvaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions. Bo Feng, Ph.D. DDI 2017 June 19-21, 2017
Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions Bo Feng, Ph.D. DDI 2017 June 19-21, 2017 Outline Background of renal transporters. Clinically observed transporter-mediated
More informationPutting Science to Work. Heptox Virtual Liver Platform
Putting Science to Work A report on TAK-875 analysis using the Heptox Virtual Liver Platform Compound MW TAK 875 524.625 EXECUTIVE SUMMARY Simulated exposures based on average drug plasma concentration
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationEVALUATION OF DRUG-DRUG INTERACTION POTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSIOLOGICALLY- BASED PHARMACOKINETIC MODEL
Drug metabolism and Pharmacokinetics/PK Sciences EVALUATIN F DRUG-DRUG INTERACTIN PTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSILGICALLY- BASED PHARMACKINETIC MDEL Imad Hanna,
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationQuantitative Evaluation of the Effect of P-Glycoprotein on Oral Drug Absorption
Quantitative Evaluation of the Effect of P-Glycoprotein on Oral Drug Absorption -Assessment of Drug Permeability to Rat Small Intestine- College of Pharmacy, Setsunan University, Osaka, Japan Yoshiyuki
More information3. P450 Drug Metabolism DDIs: Induction
35 3. P450 Drug Metabolism DDIs: Induction General Introductiona and Definition of a DDI: A drug-drug interaction (DDI) occurs when two drugs, each of which is safe and efficacious alone at their respective
More informationPhysiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions s
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2017/08/31/dmd.117.076455.dc1 1521-009X/45/11/1156 1165$25.00 https://doi.org/10.1124/dmd.117.076455 DRUG
More informationBridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Cocultured Human Hepatocyte System, HepatoPac
1521-009X/42/3/394 406$25.00 http://dx.doi.org/10.1124/dmd.113.055897 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 42:394 406, March 2014 Copyright ª 2014 by The American Society for Pharmacology
More informationDeuteration of Drugs for Pharmacokintic Enhancement: Considerations Essential for Success
Deuteration of Drugs for Pharmacokintic Enhancement: Considerations Essential for Success Alvin D.. Vaz Alfin D. Vaz Pfizer Global Research and Development Groton, CT, USA Collaborators: Raman Sharma,
More informationPrediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma S
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/20/0/06/dmd.0.036400.dc 0090-9556//3904-59 602$20.00 DRUG METABOLISM AND DISPOSITION Vol. 39, No. 4 Copyright
More informationsonidegib (LDE225) with perpetrators of CYP3A in cancer patients Heidi J. Einolf, Jocelyn Zhou, Christina Won, Lai Wang, Sam Rebello
A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients Heidi J. Einolf, Jocelyn Zhou, Christina
More informationCase #1. Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals
Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University School of Medicine
More informationThe Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives
Supplement Article The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives The Journal of Clinical Pharmacology
More informationBasic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester
Basic Concepts in Pharmacokinetics Leon Aarons Manchester Pharmacy School University of Manchester Objectives 1. Define pharmacokinetics 2. Describe absorption 3. Describe distribution 4. Describe elimination
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationAn Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes
9-9556/11/398-137 1387$25. DRUG METABOLISM AND DISPOSITION Vol. 39, No. 8 Copyright 211 by The American Society for Pharmacology and Experimental Therapeutics 38596/3724 DMD 39:137 1387, 211 Printed in
More informationIn Vitro In Vivo Extrapolation (IVIVE): Why It Is Not As Easy As You May Think
EMA Workshop on MPS - 2017 In Vitro In Vivo Extrapolation (IVIVE): Why It Is Not As Easy As You May Think Amin Rostami Professor of Systems Pharmacology University of Manchester, UK & Chief Scientific
More informationChris Bohl, Ph.D. Global Technical Support Manager- Products
Chris Bohl, Ph.D. Global Technical Support Manager- Products cbohl1@xenotechllc.com Sekisui XenoTech Overview GLP-compliant in vitro ADME-DMPK CRO founded in 1994 at the University of Kansas Medical Center
More informationMechanistic Modeling of in vitro Assays to Improve in vitro/in vivo Extrapolation
Mechanistic Modeling of in vitro Assays to Improve in vitro/in vivo Extrapolation Grace Fraczkiewicz Viera Lukacova Jim Mullin 1 OVERVIEW MembranePlus a software platform for simulation of in vitro transport
More informationSimulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
Citation: CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 250 257; VC 2016 ASCPT All rights reserved doi:10.1002/psp4.12070 ORIGINAL ARTICLE Simulation and Prediction of the Drug-Drug Interaction Potential
More informationInvolvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 S. Furuta 1, E. Kamada 1, T. Sugimoto 1, Y. Kawabata 1, X. C. Wu 2, J. Skibbe 3, E. Usuki 3, A. Parkinson 3 and
More informationEffects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program
Effects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program `Office of Clinical Research Training and Medical Education National
More information